Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (131-140 of 509) with videos related to

Pageof 51
Sort By:
The American Journal of Psychiatry|June 5, 2013
Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetesPelle L Ishøy, Filip K Knop, Tina Vilsbøll, et al.
Diabetes, Obesity & Metabolism|July 22, 2014
Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potentialA Brønden, M Hansen, D P Sonne, et al.
The Journal of Clinical Endocrinology and Metabolism|August 22, 2014
Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humansAnne Nissen, Mikkel Christensen, Filip K Knop, et al.
The Journal of Clinical Endocrinology and Metabolism|February 10, 2012
Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjectsKatrine B Hansen, Tina Vilsbøll, Jonatan I Bagger, et al.
Acta Diabetologica|December 14, 2011
Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutideA Faurschou, F K Knop, J P Thyssen, et al.
Diabetes, Obesity & Metabolism|June 7, 2016
Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metforminEmilie Bahne, Morten Hansen, Andreas Brønden, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 22, 2021
Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinicKatrine B Hansen, Mathilde Svendstrup, Asger Lund, et al.
BMC Research Notes|June 3, 2014
Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case reportFilip K Knop, Asger Lund, Sten Madsbad, et al.
Diabetes, Obesity & Metabolism|March 25, 2021
Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetesJohn B Buse, Ingrid Holst, Filip K Knop, et al.
JOP : Journal of the Pancreas|September 7, 2010
The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiencyFilip K Knop, Tina Vilsbøll, Asger Lund, et al.
Pageof 51

Showing results (131-140 of 509) with videos related to

Sort By:
Pageof 51
The American Journal of Psychiatry|June 5, 2013
Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetesPelle L Ishøy, Filip K Knop, Tina Vilsbøll, et al.
Diabetes, Obesity & Metabolism|July 22, 2014
Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potentialA Brønden, M Hansen, D P Sonne, et al.
The Journal of Clinical Endocrinology and Metabolism|August 22, 2014
Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humansAnne Nissen, Mikkel Christensen, Filip K Knop, et al.
The Journal of Clinical Endocrinology and Metabolism|February 10, 2012
Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjectsKatrine B Hansen, Tina Vilsbøll, Jonatan I Bagger, et al.
Acta Diabetologica|December 14, 2011
Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutideA Faurschou, F K Knop, J P Thyssen, et al.
Diabetes, Obesity & Metabolism|June 7, 2016
Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metforminEmilie Bahne, Morten Hansen, Andreas Brønden, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 22, 2021
Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinicKatrine B Hansen, Mathilde Svendstrup, Asger Lund, et al.
BMC Research Notes|June 3, 2014
Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case reportFilip K Knop, Asger Lund, Sten Madsbad, et al.
Diabetes, Obesity & Metabolism|March 25, 2021
Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetesJohn B Buse, Ingrid Holst, Filip K Knop, et al.
JOP : Journal of the Pancreas|September 7, 2010
The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiencyFilip K Knop, Tina Vilsbøll, Asger Lund, et al.
Pageof 51